Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $33.95 million. The enterprise value is -$46.91 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 51.78 million shares outstanding. The number of shares has increased by 136.13% in one year.
| Current Share Class | 51.78M |
| Shares Outstanding | 51.78M |
| Shares Change (YoY) | +136.13% |
| Shares Change (QoQ) | +15.50% |
| Owned by Insiders (%) | 14.07% |
| Owned by Institutions (%) | 17.05% |
| Float | 25.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.66 |
| Forward PS | 1.53 |
| PB Ratio | 3.21 |
| P/TBV Ratio | 3.21 |
| P/FCF Ratio | 1.63 |
| P/OCF Ratio | 1.63 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.96 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.37 |
| Interest Coverage | -569.57 |
Financial Efficiency
Return on equity (ROE) is -297.84% and return on invested capital (ROIC) is -133.57%.
| Return on Equity (ROE) | -297.84% |
| Return on Assets (ROA) | -38.21% |
| Return on Invested Capital (ROIC) | -133.57% |
| Return on Capital Employed (ROCE) | -101.57% |
| Revenue Per Employee | $144,906 |
| Profits Per Employee | -$848,484 |
| Employee Count | 64 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.13% in the last 52 weeks. The beta is 0.02, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -36.13% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 40.63 |
| Average Volume (20 Days) | 914,261 |
Short Selling Information
The latest short interest is 791,482, so 1.53% of the outstanding shares have been sold short.
| Short Interest | 791,482 |
| Short Previous Month | 1.22M |
| Short % of Shares Out | 1.53% |
| Short % of Float | 3.17% |
| Short Ratio (days to cover) | 0.30 |
Income Statement
In the last 12 months, XLO had revenue of $9.27 million and -$54.30 million in losses. Loss per share was -$0.83.
| Revenue | 9.27M |
| Gross Profit | 9.27M |
| Operating Income | -56.96M |
| Pretax Income | -65.53M |
| Net Income | -54.30M |
| EBITDA | -55.26M |
| EBIT | -56.96M |
| Loss Per Share | -$0.83 |
Full Income StatementBalance Sheet
The company has $89.07 million in cash and $7.86 million in debt, giving a net cash position of $81.21 million or $1.57 per share.
| Cash & Cash Equivalents | 89.07M |
| Total Debt | 7.86M |
| Net Cash | 81.21M |
| Net Cash Per Share | $1.57 |
| Equity (Book Value) | 10.70M |
| Book Value Per Share | 0.21 |
| Working Capital | 45.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $21.10 million and capital expenditures -$58,000, giving a free cash flow of $21.04 million.
| Operating Cash Flow | 21.10M |
| Capital Expenditures | -58,000 |
| Free Cash Flow | 21.04M |
| FCF Per Share | $0.41 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -614.16% |
| Pretax Margin | -585.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 226.91% |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -136.13% |
| Shareholder Yield | -136.13% |
| Earnings Yield | -158.32% |
| FCF Yield | 61.35% |
Analyst Forecast
The average price target for XLO is $4.00, which is 510.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.00 |
| Price Target Difference | 510.04% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 9.75% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XLO has an Altman Z-Score of -6.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.29 |
| Piotroski F-Score | 2 |